30
Participants
Start Date
May 30, 2019
Primary Completion Date
January 30, 2022
Study Completion Date
April 30, 2022
PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER